Loss of MAP3K7, CHD1 Expression Spur Recurrence in Prostate Cancer Loss of MAP3K7, CHD1 Expression Spur Recurrence in Prostate Cancer

Loss of MAP3K7 protein expression, seen in about 40% of prostate cancer patients, is a major driver of prostate tumor aggressiveness and should be considered for inclusion in management algorithms, researchers say.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news